Chagas disease in the United States: a public health approach

C Bern, LA Messenger, JD Whitman… - Clinical microbiology …, 2019 - Am Soc Microbiol
Trypanosoma cruzi is the etiological agent of Chagas disease, usually transmitted by
triatomine vectors. An estimated 20 to 30% of infected individuals develop potentially lethal …

Navigating drug repurposing for Chagas disease: advances, challenges, and opportunities

EOJ Porta, K Kalesh, PG Steel - Frontiers in pharmacology, 2023 - frontiersin.org
Chagas disease is a vector-borne illness caused by the protozoan parasite Trypanosoma
cruzi (T. cruzi). It poses a significant public health burden, particularly in the poorest regions …

Short-course combination treatment for experimental chronic Chagas disease

S González, RJ Wall, J Thomas, S Braillard… - Science translational …, 2023 - science.org
Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, affects millions of
people in the Americas and across the world, leading to considerable morbidity and …

Chagas Disease Ecology in the United States: Recent Advances in Understanding Trypanosoma cruzi Transmission Among Triatomines, Wildlife, and Domestic …

RE Busselman, SA Hamer - Annual review of animal …, 2022 - annualreviews.org
Chagas disease, a neglected tropical disease present in the Americas, is caused by the
parasite Trypanosoma cruzi and is transmitted by triatomine kissing bug vectors. Hundreds …

[HTML][HTML] Immunity and vaccine development efforts against Trypanosoma cruzi

LE Rios, JC Vázquez-Chagoyán, AO Pacheco… - Acta tropica, 2019 - Elsevier
Trypanosoma cruzi (T. cruzi) is the causative agent for Chagas disease (CD). There is a
critical lack of methods for prevention of infection or treatment of acute infection and chronic …

Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas …

J Altcheh, L Castro, JC Dib, U Grossmann… - PLoS neglected …, 2021 - journals.plos.org
Nifurtimox is a recommended treatment for Chagas disease, but data from treated children
are limited. We investigated the efficacy, safety and tolerability of nifurtimox administered as …

Natural-product-based solutions for tropical infectious diseases

O Adegboye, MA Field, A Kupz, S Pai… - Clinical microbiology …, 2021 - Am Soc Microbiol
About half of the world's population and 80% of the world's biodiversity can be found in the
tropics. Many diseases are specific to the tropics, with at least 41 diseases caused by …

Efficacy and safety of nifurtimox in pediatric patients with Chagas disease: results at 4-year follow-up in a prospective, historically controlled study (CHICO SECURE)

J Altcheh, V Sierra, T Ramirez… - Antimicrobial Agents …, 2023 - Am Soc Microbiol
Nifurtimox is recommended for the treatment of Chagas disease; however, long-term follow-
up data are scarce. This prolonged follow-up phase of the prospective, historically …

Of drugs and trypanosomatids: new tools and knowledge to reduce bottlenecks in drug discovery

A Bhattacharya, A Corbeil, RL do Monte-Neto… - Genes, 2020 - mdpi.com
Leishmaniasis (Leishmania species), sleeping sickness (Trypanosoma brucei), and Chagas
disease (Trypanosoma cruzi) are devastating and globally spread diseases caused by …

Preclinical advances and the immunophysiology of a new therapeutic Chagas disease vaccine

KM Jones, C Poveda, L Versteeg… - Expert review of …, 2022 - Taylor & Francis
Introduction Chronic infection with the protozoal parasite Trypanosoma cruzi leads to a
progressive cardiac disease, known as chronic Chagasic cardiomyopathy (CCC). A new …